Nov 13, 2009 (SmarTrend(R) News Watch via COMTEX) ----11/13/2009 - Lexicon Pharmaceuticals (NASDAQ:LXRX) announced that the company's investigational new drug, LX1031, demonstrated positive results in a study. Results shows that the treatment with one gram of LX1031 four times daily produced a statistically significant improvement in global assessment of relief of irritable bowel syndrome. Chief scientific officer Dr. Brian Zambrowicz said, "Treatment with LX1031 reduced symptoms of IBS in this clinical trial, and holds promise for patients with this disease. We believe the fact that the clinical benefit was correlated to the reduction in the 5-HIAA biomarker validates our therapeutic strategy of inhibiting TPH as a novel treatment option for patients with IBS. The overall safety and efficacy profile observed to date supports further development of this novel mechanism in IBS."

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

Copyright, Comtex News Network, Inc. 2009
   
   **********************************************************************
   
   As of Monday, 11-09-2009 23:59, the latest Comtex SmarTrend� Alert, 
   an automated pattern recognition system, indicated a DOWNTREND on 
   10-02-2009 for LXRX @ $1.88.
   
   For more information on SmarTrend, contact your market data
   provider or go to www.mysmartrend.com
   
   SmarTrend is a registered trademark of Comtex News Network, Inc.
   Copyright � 2004-2009 Comtex News Network, Inc. All rights reserved.